Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Research & Development (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Research & Development for 9 consecutive years, with $101.9 million as the latest value for Q3 2025.

  • Quarterly Research & Development rose 3.78% to $101.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $339.7 million through Sep 2025, down 1.96% year-over-year, with the annual reading at $418.8 million for FY2025, 5.63% up from the prior year.
  • Research & Development for Q3 2025 was $101.9 million at Denali Therapeutics, down from $102.7 million in the prior quarter.
  • The five-year high for Research & Development was $128.8 million in Q1 2023, with the low at $18.8 million in Q4 2022.
  • Average Research & Development over 5 years is $81.7 million, with a median of $89.7 million recorded in 2023.
  • The sharpest move saw Research & Development tumbled 72.3% in 2022, then soared 164.89% in 2023.
  • Over 5 years, Research & Development stood at $67.9 million in 2021, then plummeted by 72.3% to $18.8 million in 2022, then skyrocketed by 164.89% to $49.8 million in 2023, then tumbled by 62.25% to $18.8 million in 2024, then skyrocketed by 442.29% to $101.9 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $101.9 million, $102.7 million, and $116.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.